APA aipamena

Karachaliou, N., Codony-Servat, J., Teixidó, C., Pilotto, S., Drozdowskyj, A., Codony-Servat, C., . . . Rosell, R. (2015). BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep.

Chicago Style aipamena

Karachaliou, Niki, et al. "BIM and MTOR Expression Levels Predict Outcome to Erlotinib in EGFR-mutant Non-small-cell Lung Cancer." Sci Rep 2015.

MLA aipamena

Karachaliou, Niki, et al. "BIM and MTOR Expression Levels Predict Outcome to Erlotinib in EGFR-mutant Non-small-cell Lung Cancer." Sci Rep 2015.